Sangui Biotech International Stock Buy Hold or Sell Recommendation
| SGBI Stock | USD 0 0.00 0.00% |
Given the investment horizon of 90 days and your way above-average risk tolerance, our recommendation regarding Sangui Biotech International is 'Strong Sell'. The recommendation algorithm takes into account all of Sangui Biotech's available fundamental, technical, and predictive indicators you will find on this site.
Check out Sangui Biotech Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Sangui and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Sangui Biotech International. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
Sangui |
Execute Sangui Biotech Buy or Sell Advice
The Sangui recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Sangui Biotech International. Macroaxis does not own or have any residual interests in Sangui Biotech International or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Sangui Biotech's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Not Rated
Sangui Biotech Trading Alerts and Improvement Suggestions
| Sangui Biotech Inter generated a negative expected return over the last 90 days | |
| Sangui Biotech Inter has some characteristics of a very speculative penny stock | |
| Sangui Biotech International currently holds 48.9 K in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. Sangui Biotech Inter has a current ratio of 0.07, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Sangui Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Sangui Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sangui Biotech Inter sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sangui to invest in growth at high rates of return. When we think about Sangui Biotech's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 69.19 K. Net Loss for the year was (63.34 K) with profit before overhead, payroll, taxes, and interest of 69.19 K. | |
| Sangui Biotech International currently holds about 30.47 K in cash with (140.46 K) of positive cash flow from operations. | |
| Roughly 13.0% of Sangui Biotech outstanding shares are owned by corporate insiders |
Sangui Biotech Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Sangui Biotech or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Sangui Biotech's price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Sangui pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.00 | |
β | Beta against Dow Jones | 0.00 | |
σ | Overall volatility | 0.00 | |
Ir | Information ratio | 0.00 |
Sangui Biotech Volatility Alert
At this time Sangui Biotech International exhibits very low volatility. Sangui Biotech International is a penny stock. Even though Sangui Biotech may be a good instrument to invest, many penny pink sheets are speculative instruments that are subject to artificial stock promotions. Please make sure you fully understand upside and downside scenarios of investing in Sangui Biotech International or similar risky assets. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings,sudden promotions and many other similar artificial hype indicators. We also encourage traders to check work history of company executives before investing in high-volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Sangui instrument if you perfectly time your entry and exit. However, remember that penny pink sheets that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Sangui Biotech Fundamentals Vs Peers
Comparing Sangui Biotech's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Sangui Biotech's direct or indirect competition across all of the common fundamentals between Sangui Biotech and the related equities. This way, we can detect undervalued stocks with similar characteristics as Sangui Biotech or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Sangui Biotech's fundamental indicators could also be used in its relative valuation, which is a method of valuing Sangui Biotech by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Sangui Biotech to competition |
| Fundamentals | Sangui Biotech | Peer Average |
| Return On Asset | -0.64 | -0.14 |
| Profit Margin | (1.27) % | (1.27) % |
| Operating Margin | (1.50) % | (5.51) % |
| Current Valuation | 1.68 M | 16.62 B |
| Shares Outstanding | 209.9 M | 571.82 M |
| Shares Owned By Insiders | 13.03 % | 10.09 % |
| Price To Earning | (18.33) X | 28.72 X |
| Price To Book | 46.44 X | 9.51 X |
| Price To Sales | 10.09 X | 11.42 X |
| Revenue | 69.19 K | 9.43 B |
| Gross Profit | 69.19 K | 27.38 B |
| EBITDA | (18.44 K) | 3.9 B |
| Net Income | (63.34 K) | 570.98 M |
| Cash And Equivalents | 30.47 K | 2.7 B |
| Total Debt | 48.9 K | 5.32 B |
| Debt To Equity | 0.05 % | 48.70 % |
| Current Ratio | 0.07 X | 2.16 X |
| Book Value Per Share | (0) X | 1.93 K |
| Cash Flow From Operations | (140.46 K) | 971.22 M |
| Number Of Employees | 2 | 18.84 K |
| Beta | 0.22 | -0.15 |
| Market Capitalization | 902.58 K | 19.03 B |
| Total Asset | 130.79 K | 29.47 B |
| Retained Earnings | (37 M) | 9.33 B |
| Net Asset | 130.79 K |
Sangui Biotech Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Sangui . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 0.0015 | |||
| Day Typical Price | 0.0015 |
About Sangui Biotech Buy or Sell Advice
When is the right time to buy or sell Sangui Biotech International? Buying financial instruments such as Sangui Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Sangui Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Warren Buffett Holdings Thematic Idea Now
Warren Buffett Holdings
A long-term portfolio of publicly-traded stocks on US exchanges that are owned by Warren Buffett's holding company Berkshire Hathaway. The Warren Buffett Holdings theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Warren Buffett Holdings Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Sangui Pink Sheet
Sangui Biotech financial ratios help investors to determine whether Sangui Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sangui with respect to the benefits of owning Sangui Biotech security.